Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Expo on Google News
SYS-CON.TV
Cloud Expo & Virtualization 2009 East
PLATINUM SPONSORS:
IBM
Smarter Business Solutions Through Dynamic Infrastructure
IBM
Smarter Insights: How the CIO Becomes a Hero Again
Microsoft
Windows Azure
GOLD SPONSORS:
Appsense
Why VDI?
CA
Maximizing the Business Value of Virtualization in Enterprise and Cloud Computing Environments
ExactTarget
Messaging in the Cloud - Email, SMS and Voice
Freedom OSS
Stairway to the Cloud
Sun
Sun's Incubation Platform: Helping Startups Serve the Enterprise
POWER PANELS:
Cloud Computing & Enterprise IT: Cost & Operational Benefits
How and Why is a Flexible IT Infrastructure the Key To the Future?
Click For 2008 West
Event Webcasts
Discriminatory Vaccine Policy Based on Falsified Paper

WASHINGTON, Nov. 17, 2012 /PRNewswire/ -- CoMeD -- As the Inspector General for Health and Human Services names vaccine researcher Poul Thorsen as one of its "Most Wanted" fugitives, the defense of mercury as 'safe in vaccines' seems to be crumbling.

In 2010, the Coalition for Mercury-free Drugs (CoMeD, Inc.) submitted an allegation to the Inspector General, that studies showing mercury-containing vaccines to be safe, are fraudulent. Now, a new "wanted" posted featuring Danish vaccine researcher Poul Thorsen, issued by the Inspector General  (HHS-OIG), offers proof this allegation is credible.

It is estimated that Poul Thorsen embezzled at least one million dollars of grant money from the CDC, while he co-authored, "Thimerosal and the occurrence of autism …".  CDC documents, obtained through FOIA, also show that Thorsen and his co-authors concealed the fact that autism declined in Denmark after Thimerosal was removed from the Danish vaccine program. 

Today, the US Government and the World Health Organization defend the ongoing use of Thimerosal, the highly toxic mercury-based vaccine preservative, based on a handful of industry-sponsored statistical studies, including Thorsen's. The manufacturer's Material Safety Data Sheet for Thimerosal, however, lists mental retardation as a possible outcome from exposure in utero and in children.  

Based on Thorsen's public conclusion, Dr. Jose Cordero, former US Assistant Surgeon General, declared that "(Thorsen's) Danish study…provide(s) one strong piece of evidence that Thimerosal is not causally linked to autism." Disturbingly, this study also helped the Institute of Medicine reach its 2004 declaration that mercury in vaccines is unrelated to the autism epidemic.

Globally, the proponents for Thimerosal-preserved vaccines are using this questionable research to justify providing mercury-preserved vaccines to developing countries.  While children in developed, western, nations receive mercury-free vaccine formulations, children in developing countries receive many mercury-preserved ones.

At the fourth meeting of the United Nations Intergovernmental Negotiating Committee (INC4) to write a global treaty on mercury, Rev. Lisa K. Sykes, President of CoMeD, Inc., termed this double standard in vaccine safety a form of discrimination based on economics and nationality.  It now seems this discrimination is also based upon falsified data and criminal conduct.

Despite this, the US National Institutes of Health and Centers for Disease Control and Prevention continue to collaborate with Poul Thorsen, using federal funds.  Thorsen remains in Denmark, and no date for his extradition has been made public.

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Cloud Developer Stories
Organizations today increasingly rely on Application Performance Management (APM) tools like New Relic to respond to end user complaints, and to track system latency and other key application metrics. With this data, users can often confirm if the application is running slowly an...
Racemi is announcing this update to its migration technology that makes the free online migrations to IBM SoftLayer easier than ever by adding a SoftLayer Object Storage image option for enhanced security and compliance.
Software AG helps organizations transform into Digital Enterprises, so they can differentiate from competitors and better engage customers, partners and employees. Using the Software AG Suite, companies can close the gap between business and IT to create digital systems of differ...
In this challenging environment, a combination of automated integration testing and test virtualization can enable test teams to improve software quality and keep up with the rate of change. This white paper helps address these needs by describing the benefits that can be gained ...
The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long development cycles that produce software that...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021



SYS-CON Featured Whitepapers
ADS BY GOOGLE

Breaking Cloud Computing News

NEW YORK, Sept. 30, 2014 /PRNewswire/ -- ARK Investment Management (ARK) is pleased to announce t...